Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 1382805, 11 pages
https://doi.org/10.1155/2017/1382805
Research Article

Amelioration of Inflammatory Cytokines Mix Stimulation: A Pretreatment of CD137 Signaling Study on VSMC

Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China

Correspondence should be addressed to Jin Chuan Yan; moc.liamtoh@nauhcnijnay

Received 5 November 2016; Accepted 11 January 2017; Published 9 February 2017

Academic Editor: Joseph Raffetto

Copyright © 2017 Wei Zhong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Dharmadhikari, M. Wu, N. S. Abdullah et al., “CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses,” OncoImmunology, vol. 5, no. 4, Article ID e1113367, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Wilcox, K. Tamada, S. E. Strome, and L. Chen, “Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity,” Journal of Immunology, vol. 169, no. 8, pp. 4230–4236, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. J. L. Cannons, P. Lau, B. Ghumman et al., “4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy,” Journal of Immunology, vol. 167, no. 3, pp. 1313–1324, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Shindo, K. Yoshimura, A. Kuramasu et al., “Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor,” Anticancer Research, vol. 35, no. 1, pp. 129–136, 2015. View at Google Scholar · View at Scopus
  5. P. Kroon, J. Gadiot, M. Peeters et al., “Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma,” Cancer Immunology, Immunotherapy, vol. 65, no. 6, pp. 753–763, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. P. S. Olofsson, L. Å. Söderström, D. Wågsäter et al., “CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice,” Circulation, vol. 117, no. 10, pp. 1292–1301, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. H. J. Jeon, J.-H. Choi, I.-H. Jung et al., “CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice,” Circulation, vol. 121, no. 9, pp. 1124–1133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. I.-H. Jung, J.-H. Choi, J. Jin et al., “CD137-inducing factors from T cells and macrophages accelerate the destabilization of atherosclerotic plaques in hyperlipidemic mice,” FASEB Journal, vol. 28, no. 11, pp. 4779–4791, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Yan, C. Wang, Z. Wang, and W. Yuan, “The effect of CD137-CD137 ligand interaction on phospholipase C signaling pathway in human endothelial cells,” Chemico-Biological Interactions, vol. 206, no. 2, pp. 256–261, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. G. K. Hansson, “Inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1626–1695, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. R. Bennett, S. Sinha, and G. K. Owens, “Vascular smooth muscle cells in atherosclerosis,” Circulation Research, vol. 118, no. 4, pp. 692–702, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Cheng, X. Liu, J. Yang et al., “MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation,” Circulation Research, vol. 105, no. 2, pp. 158–166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Pugliese, C. Iacobini, C. B. Fantauzzi, and S. Menini, “The dark and bright side of atherosclerotic calcification,” Atherosclerosis, vol. 238, no. 2, pp. 220–230, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Yan, Y. Yin, W. Zhong, C. Wang, and Z. Wang, “CD137 regulates NFATc1 expression in mouse VSMCs through TRAF6/NF- B p65 signaling pathway,” Mediators of Inflammation, vol. 2015, Article ID 639780, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Labiano, A. Palazón, E. Bolaños et al., “Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism,” OncoImmunology, vol. 5, no. 1, Article ID e1062967, 2015. View at Publisher · View at Google Scholar
  16. J. Yan, C. Wang, R. Chen, and H. Yang, “Clinical implications of elevated serum soluble CD137 levels in patients with acute coronary syndrome,” Clinics, vol. 68, no. 2, pp. 193–198, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. T. H. Watts, “TNF/TNFR family members in costimulation of T cell responses,” Annual Review of Immunology, vol. 23, pp. 23–68, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Wang, W.-Y. Zhang, Q.-W. Han et al., “Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells,” Clinical Immunology, vol. 155, no. 2, pp. 160–175, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. H. B. Barsoumian, E. S. Yolcu, and H. Shirwan, “4-1BB signaling in conventional T cells drives IL-2 production that overcomes CD4+CD25+FoxP3+ T regulatory cell suppression,” PLOS ONE, vol. 11, no. 4, Article ID e0153088, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. M.-C. St Rose, R. A. Taylor, S. Bandyopadhyay et al., “CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion,” Immunology and Cell Biology, vol. 91, no. 2, pp. 173–183, 2013. View at Publisher · View at Google Scholar · View at Scopus